ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection
Launched by VANDA PHARMACEUTICALS · Mar 27, 2020
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged 18-90
- • Confirmed laboratory COVID-19 infection by RT-PCR
- • Meeting severe or critical criteria of COVID-19 infection as defined at treating hospital
- • Confirmed pneumonia by chest radiograph or computed tomography
- • Fever defined as temperature ≥ 36.6 °C armpit, ≥ 37.2 °C oral, or ≥ 37.8 °C rectal
- • Oxygen saturation less than 92%
- Exclusion Criteria:
- • Recent use of illicit drugs or alcohol abuse
- • Known allergy to tradipitant or other neurokinin-1 antagonists
- • Pregnancy
- • Known HIV, HBV, or HCV infection
- • Malignant tumor, other serious systemic diseases
- • Inability to provide informed consent or to have an authorized relative or designated person provide informed consent, or to comply with the protocol requirements
About Vanda Pharmaceuticals
Vanda Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with unmet medical needs, particularly in the fields of psychiatry and sleep disorders. With a strong focus on precision medicine, Vanda leverages cutting-edge research and clinical trial methodologies to advance novel treatments that improve patient outcomes. The company's commitment to scientific excellence and patient-centric approaches positions it as a leader in delivering transformative healthcare solutions. Through its robust pipeline and strategic partnerships, Vanda aims to enhance the quality of life for individuals affected by complex medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials